Center for AIDS Prevention Studies, University of California San Francisco, San Francisco, California, USA.
Women's Global Health Imperative, RTI International, Berkeley, California, USA
BMJ Open. 2023 Oct 6;13(10):e077676. doi: 10.1136/bmjopen-2023-077676.
INTRODUCTION: Young adults with HIV (YWH) experience worse clinical outcomes than adults and have high rates of substance use (SU) and mental illness that impact their engagement in care and adherence to antiretroviral therapy (ART). The intervention for Virologic Suppression in Youth (iVY) aims to address treatment engagement/adherence, mental health (MH) and SU in a tailored manner using a differentiated care approach that is youth friendly. Findings will provide information about the impact of iVY on HIV virological suppression, MH and SU among YWH who are disproportionately impacted by HIV and at elevated risk for poor health outcomes. METHODS AND ANALYSIS: The iVY study will test the effect of a technology-based intervention with differing levels of resource requirements (ie, financial and personnel time) in a randomised clinical trial with an adaptive treatment strategy among 200 YWH (18-29 years old). The primary outcome is HIV virological suppression measured via dried blood spot. This piloted and protocolised intervention combines: (1) brief weekly sessions with a counsellor via a video-chat platform (video-counselling) to discuss MH, SU, HIV care engagement/adherence and other barriers to care; and (2) a mobile health app to address barriers such as ART forgetfulness, and social isolation. iVY has the potential to address important, distinct and changing barriers to HIV care engagement (eg, MH, SU) to increase virological suppression among YWH at elevated risk for poor health outcomes. ETHICS AND DISSEMINATION: This study and its protocols have been approved by the University of California, San Francisco Institutional Review Board. Study staff will work with a Youth Advisory Panel to disseminate results to YWH, participants and the academic community. TRIAL REGISTRATION NUMBER: NCT05877729.
简介:与成年人相比,患有艾滋病的年轻人(YWH)的临床结局更差,且他们物质使用(SU)和精神疾病的发生率较高,这会影响他们参与治疗和对抗逆转录病毒治疗(ART)的依从性。青年病毒学抑制干预(iVY)旨在通过使用针对年轻人友好的差异化护理方法,以定制的方式解决治疗参与/依从性、心理健康(MH)和 SU 问题。研究结果将提供有关 iVY 对 HIV 病毒学抑制、YWH 的 MH 和 SU 影响的信息,这些 YWH 受到 HIV 的不成比例影响,且健康状况不佳的风险较高。
方法和分析:iVY 研究将通过一项具有适应性治疗策略的随机临床试验,在 200 名 YWH(18-29 岁)中,测试基于技术的干预措施在不同资源需求(即财务和人员时间)水平下的效果。主要结局是通过干血斑测量的 HIV 病毒学抑制。该经过试点和方案设计的干预措施结合了以下内容:(1)通过视频聊天平台每周与顾问进行简短的视频咨询,讨论 MH、SU、HIV 护理参与/依从性和其他护理障碍;(2)通过移动健康应用程序解决 ARV 遗忘和社交孤立等障碍。iVY 有可能解决与 HIV 护理参与相关的重要、独特和不断变化的障碍(例如,MH、SU),以提高健康状况不佳风险较高的 YWH 的病毒学抑制率。
伦理和传播:本研究及其方案已获得加利福尼亚大学旧金山分校机构审查委员会的批准。研究人员将与青年咨询小组合作,将研究结果传播给 YWH、参与者和学术界。
临床试验注册号:NCT05877729。
AIDS Patient Care STDS. 2024-5
Drug Alcohol Depend. 2021-9-1
J Int AIDS Soc. 2021-6
Int J Environ Res Public Health. 2021-4-15
J Acquir Immune Defic Syndr. 2020-5-1